Research programme: anti-infectives - NovaBay Pharmaceuticals

Drug Profile

Research programme: anti-infectives - NovaBay Pharmaceuticals

Alternative Names: Aganocide®; NVC-612; NVC-638; NVC-704; NVC-727

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovaBay Pharmaceuticals
  • Class Alkanesulfonic-acids; Chloramines; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bacterial infections; Mycoses; Onychomycosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Topical)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in USA (Topical)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Onychomycosis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top